Impax Names Douglas S. Boothe President of Generics Division

July 21, 2016

-- Experienced Executive Added to Advance Robust Generic Portfolio --

HAYWARD, Calif., July 21, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has filled a key executive leadership role, appointing Douglas S. Boothe as president of the Generics Division effective August 1, 2016. Mr. Boothe will join the Company's Executive Committee, reporting directly to the Chief Executive Officer (CEO) and be responsible for all aspects of the generic business.

Impax Names Douglas S. Boothe President of Generics Division

"The addition of this seasoned industry executive will enhance our senior management team and is critical in the execution of our focused initiatives to build long-term stockholder value and sustainable success," stated Fred Wilkinson, President and CEO of Impax. "Doug is an accomplished executive with extensive generic pharmaceutical leadership and business development experience that will be instrumental in growing our generics business. We are delighted that Doug is joining the Company at an important time, as we expand our generics portfolio through the pending acquisition of products from Teva Pharmaceutical Industries Ltd. and affiliates of Allergan plc, and prepare the strategies to maximize the return from our near term potential ANDA approvals."

Prior to Impax, Mr. Boothe, 52, served as Executive Vice President and General Manager, Perrigo Company Plc, where he had responsibility for US Pharmaceuticals, including Generics and Specialty. Previously, Mr. Boothe served as Chief Executive Officer of Actavis, Inc. from August 2008 to December 2012 and as Executive Vice President and Chief Operating Officer from 2006 to 2008. Prior to that position, Mr. Boothe held various senior positions in strategic planning and business development for Alpharma Inc., Pharmacia Corporation and Xerox Corporation, and recently served as a Director of the Generic Pharmaceutical Association. Mr. Boothe holds a BSE in Mechanical & Aerospace Engineering from Princeton University and an MBA from the University of Pennsylvania's Wharton School of Business.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at:

Company Contact: 
Mark Donohue
Investor Relations and Corporate Communications      
(215) 558-4526                                                      

Photo -


To view the original version on PR Newswire, visit:

SOURCE Impax Laboratories, Inc.